The positive clinical data and FDA priority review are significant catalysts for Vera Therapeutics, indicating potential for a major commercial launch in mid-2026. However, the substantial increase in net loss and operating expenses signals high ongoing costs. Traders should monitor the company's cash burn rate and upcoming clinical milestones, as the stock may react strongly to the PDUFA decision in July 2026.
Price Chart
Executive Summary
Vera Therapeutics reported strong business progress with positive Phase 3 data for atacicept in IgA nephropathy, FDA priority review granted with a PDUFA date of July 7, 2026, and a robust balance sheet from $800 million in financings. However, the company reported a significant net loss increase to $299.6 million in 2025 from $152.1 million in 2024, driven by higher R&D and G&A expenses.
Key Financial Metrics
Key Facts
- Positive Phase 3 data from the ORIGIN 3 study of atacicept in IgA nephropathy presented at ASN Kidney Week and published in NEJM
- FDA granted priority review to the Biologics License Application (BLA) for atacicept with a PDUFA date of July 7, 2026
- Equity and debt financings in 2025 raised $800 million in gross proceeds, strengthening the balance sheet
- Cash, cash equivalents, and marketable securities totaled $714.6 million as of December 31, 2025
- Net loss increased to $299.6 million in 2025 from $152.1 million in 2024, with net loss per diluted share rising to $4.66 from $2.75
- Net cash used in operating activities increased to $241.1 million in 2025 from $134.7 million in 2024
- Research and development expenses increased to $215.3 million in 2025 from $126.2 million in 2024
Financial Impact
Net loss increased by 97% YoY to $299.6 million; R&D expenses increased by 71% YoY; $800 million in gross proceeds from financings
Risk Factors
- High and increasing net losses could pressure the balance sheet despite recent financings
- The company remains pre-revenue with no commercial products, making it highly dependent on the success of atacicept
- Clinical trial results may not lead to regulatory approval or commercial success
- Market volatility due to insider selling activity, with 7 insider sells totaling $1.4 million in the last 30 days
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073421 |
| Document: vera-20260226.htm | 0001193125-26-073421 |
| Document: 0001193125-26-073421-index-headers.html | 0001193125-26-073421 |
| Document: 0001193125-26-073421-index.html | 0001193125-26-073421 |
| Document: 0001193125-26-073421.txt | 0001193125-26-073421 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $33.67 $34.00 | ▲ +0.98% | ▲ +0.16% | $30.13 (−10.53%) |
Aug 10, 2026 7w ago | 8-K | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | $30.13 (−0.54%) |
Aug 10, 2026 7w ago | Press Release | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | $30.13 (−0.54%) |
Jul 9, 2026 12w ago | 8-K | $42.45 $39.12 | ▼ −7.84% | ▼ −7.71% | $30.13 (−29.03%) |
Jul 7, 2026 12w ago | 8-K | $42.96 $43.13 | ▲ +0.40% | ▼ −0.16% | $30.13 (−29.88%) |
Jun 11, 2026 16w ago | Institutional Cluster | $33.65 $35.01 | ▲ +4.04% | ▲ +3.61% | $30.13 (−10.48%) |
Jun 2, 2026 17w ago | 8-K | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | $30.13 (−3.63%) |
Jun 2, 2026 17w ago | Press Release | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | $30.13 (−3.63%) |
May 7, 2026 21w ago | 8-K | $35.88 $39.15 | ▲ +9.11% | ▲ +7.61% | $30.13 (−16.04%) |
Feb 26, 2026 31w ago | 8-K | $42.35 $38.85 | ▼ −8.26% | ▼ −7.14% | $30.13 (−28.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access